Posted by ABMN Staff on May 6th, 2024
Benchmark reaffirmed their buy rating on shares of Codexis (NASDAQ:CDXS – Free Report) in a report published on Friday, Benzinga reports. They currently have a $9.00 price objective on the biotechnology company’s stock.
Separately,...
More of this article »